CA2706115A1 - Seprase as a marker for cancer - Google Patents

Seprase as a marker for cancer Download PDF

Info

Publication number
CA2706115A1
CA2706115A1 CA2706115A CA2706115A CA2706115A1 CA 2706115 A1 CA2706115 A1 CA 2706115A1 CA 2706115 A CA2706115 A CA 2706115A CA 2706115 A CA2706115 A CA 2706115A CA 2706115 A1 CA2706115 A1 CA 2706115A1
Authority
CA
Canada
Prior art keywords
cancer
seprase
marker
fragments
assessment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2706115A
Other languages
English (en)
French (fr)
Inventor
Wolfgang Rollinger
Johann Karl
Jarema Peter Kochan
Markus Roessler
Michael Tacke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Individual filed Critical Individual
Publication of CA2706115A1 publication Critical patent/CA2706115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
CA2706115A 2007-12-10 2008-12-08 Seprase as a marker for cancer Abandoned CA2706115A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07023897.7 2007-12-10
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310.9 2008-08-29
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
CA2706115A1 true CA2706115A1 (en) 2009-06-18

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2706115A Abandoned CA2706115A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Country Status (14)

Country Link
US (1) US8980573B2 (enExample)
EP (1) EP2223115B1 (enExample)
JP (1) JP5563988B2 (enExample)
KR (1) KR101202220B1 (enExample)
CN (1) CN101896818B (enExample)
AT (1) ATE524740T1 (enExample)
AU (1) AU2008335855B2 (enExample)
BR (1) BRPI0820793A2 (enExample)
CA (1) CA2706115A1 (enExample)
DK (1) DK2223115T3 (enExample)
ES (1) ES2372442T3 (enExample)
MX (1) MX2010004671A (enExample)
PL (1) PL2223115T3 (enExample)
WO (1) WO2009074275A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
CN102138074B (zh) * 2008-07-03 2014-08-13 霍夫曼-拉罗奇有限公司 用作肺癌标记物的asc
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) * 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
AU2011316986A1 (en) * 2010-10-20 2013-06-06 Rush University Medical Center Lung cancer tests
WO2012123293A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Seprase as marker for chronic obstructive pulmonary disease (copd)
ES2578477T3 (es) 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
SG11201408651TA (en) 2012-06-27 2015-01-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
ES2660438T3 (es) 2012-11-09 2018-03-22 F. Hoffmann-La Roche Ag Captura in vitro y análisis de células tumorales circulantes
MX2015006757A (es) * 2012-11-30 2015-11-30 Applied Proteomics Inc Método para la evaluación de la presencia de o riesgo de tumores de colon.
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
WO2015088947A1 (en) 2013-12-09 2015-06-18 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
KR102657306B1 (ko) 2014-12-08 2024-04-12 버그 엘엘씨 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
KR102111699B1 (ko) * 2017-09-05 2020-05-15 (주)온코태그디아그노스틱 메티오닐-티알엔에이 합성효소를 이용한 췌장암 진단 방법 및 이를 이용한 췌장암 진단 키트
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
AU2004286307A1 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
JP2008517914A (ja) * 2004-10-22 2008-05-29 ジェネンコー・インターナショナル・インク ヒトの抗体の分離方法
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式

Also Published As

Publication number Publication date
HK1150884A1 (zh) 2012-01-13
EP2223115A1 (en) 2010-09-01
AU2008335855B2 (en) 2012-08-30
PL2223115T3 (pl) 2012-02-29
CN101896818A (zh) 2010-11-24
US8980573B2 (en) 2015-03-17
JP5563988B2 (ja) 2014-07-30
WO2009074275A1 (en) 2009-06-18
CN101896818B (zh) 2016-01-20
DK2223115T3 (da) 2011-12-12
ES2372442T3 (es) 2012-01-19
US20100240081A1 (en) 2010-09-23
KR20100091212A (ko) 2010-08-18
KR101202220B1 (ko) 2012-11-16
BRPI0820793A2 (pt) 2015-06-16
EP2223115B1 (en) 2011-09-14
AU2008335855A1 (en) 2009-06-18
ATE524740T1 (de) 2011-09-15
JP2011506941A (ja) 2011-03-03
MX2010004671A (es) 2010-05-27

Similar Documents

Publication Publication Date Title
AU2008335855B2 (en) Seprase as a marker for cancer
CA2760735C (en) Use of dppiv/seprase as a marker for cancer
US10815517B2 (en) Use of DPPIV/seprase as a marker for cancer
EP2223116B1 (en) Marker panel for colorectal cancer
US9518990B2 (en) Secernin-1 as a marker for cancer
EP2071337A1 (en) Seprase as a marker for cancer
EP2380024A1 (en) Armet as a marker for cancer
US7785821B2 (en) Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer
US8951738B2 (en) CYBP as a marker for lung cancer
HK1150884B (en) Seprase as a marker for cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20220718